Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.
复制标题
作者：
Dong X;Chu D;Wang Z
纳米技术已经成为一种强大的工具，有可能将纳米医学从实验室应用到临床。纳米治疗剂是一种装载药物的纳米颗粒，其表面经过生物功能化处理后具有组织靶向性。基于EPR（增强渗透性和滞留性）效应，设计更小尺寸的纳米治疗药物被认为可以提高肿瘤靶向性。由于免疫系统具有抵抗疾病的防御机制，有一个新兴的概念，即NPs选择性地靶向免疫细胞，介导药物主动递送到疾病部位。在这篇综述中，我们将重点关注纳米治疗如何特异性靶向免疫细胞并劫持它们作为递送载体将纳米治疗药物运送到疾病组织，从而可能改善炎症，免疫疾病和癌症的现有治疗方法。我们还将讨论这种白细胞介导的纳米治疗递送新策略的挑战和机遇。
Nanotechnology has become a powerful tool to potentially translate nanomedicine from bench to bedside. Nanotherapeutics are nanoparticles (NPs) loaded with drugs and possess the property of tissue targeting after surfaces of NPs are bio-functionalized. Designing smaller size of nanotherapeutics is presumed to increase tumor targeting based on the EPR (enhanced permeability and retention) effect. Since the immune systems possess a defence mechanism to fight diseases, there is an emerging concept that NPs selectively target immune cells to mediate the active delivery of drugs into sites of disease. In this review, we will focus on a key question of how nanotherapeutics specifically target immune cells and hijack them as a delivery vehicle to transport nanotherapeutics into disease tissues, thus possibly improving current therapies in inflammation, immune disorders and cancers. We will also discuss the challenges and opportunities for this new strategy of leukocyte-mediated delivery of nanotherapeutics.